SOLICITATION NOTICE
B -- Cross-Species Comparison of Metabolic Markers in Serous Epithelial Ovarian Cancer
- Notice Date
- 5/23/2013
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP32510-59
- Archive Date
- 6/22/2013
- Point of Contact
- Afua Serwah- Asibey, Phone: 240-276-6991
- E-Mail Address
-
serwahasibeya@mail.nih.gov
(serwahasibeya@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive RM 1E142, Rockville, MD 20892. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis with Metabolon Inc., 617 Davis Dr. Ste 400, Durham, NC 27713 to assess metabolic changes observed in cases with serous epithelial ovarian cancer (SEOC) and matched controls from a population-based case-control study in Poland. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 541712 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve(12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. Ovarian cancer is the most fatal gynecologic malignancy and the fifth cause of cancer death in women. Due to lack of symptoms at early stages, most ovarian cancers are diagnosed at advanced stages and have an exceedingly poor 5-year survival rate of 28%. A recent mouse model will facilitate studying ovarian carcinogenesis to provide new etiologic and translational leads for biomarker evaluation in humans. Specifically, a highly penetrant genetically engineered mouse model for serous epithelial ovarian cancer (SEOC) was developed at the Center of Advanced Preclinical Research, Frederick National Laboratory for Cancer Research. The mouse model has several key histologic, morphologic, immunophenotypic and genetic features of human SEOC, the most common and most fatal ovarian cancer subtype. The mouse model recapitulates the intraperitoneal spreading from a primary ovarian tumor to common sites of distant metastases that are typical in human SEOC. Further, metabolic changes in the tissues from SEOC mice are similar to what has been described for tumor tissue obtained from primary epithelial ovarian carcinomas and metastatic tumors in the omentum. In the mouse model, metabolic markers measured in whole blood were altered in a prediagnostic stage of ovarian cancer development, suggesting that these markers could serve for early detection of ovarian cancers. As a first step to evaluate these markers in human ovarian cancer, it will be important to evaluate blood-based metabolic biomarkers in patients with existing disease compared to controls. If successful, NCI will move to studies with prediagnostic blood specimens to recapitulate the findings from the mouse model. The NCI seeks to compare metabolic changes associated with the development of mouse SEOC and control animals with metabolic changes observed in cases with SEOC and matched controls from a population-based case-control study in Poland. To assess the extent to which the mouse SEOC model can be used for biomarker discovery the proposed contract will cover the metabolic profiling in sera from 59 SEOC cases, 59 controls and 14 quality control samples, to serve as a cross-species comparison with metabolic profiling data from 15 compound mouse SEOC mutants at different time points during disease progression and 15 control animals. The Contractor shall conduct metabolite measurements of 282known metabolites and provide quantitative results. One aliquot of each serum sample will be shipped from the NCI biorepository to the contractor. At the facilities, 150 μL serum samples shall be analyzed simultaneously using liquid chromatography/mass spectrometry (LC/MS) followed by gas chromatography/mass spectroscopy to measure 282 known metabolites. Quantitative metabolite concentrations will be identified from the integrated raw detector counts from the mass spectrometers. Upon completion of specimen measurement and processing, quantitative metabolite concentrations shall be emailed to NCI. The proposed contractor, Metabolon Inc. has previously evaluated the mouse model using their proprietary technology. Comparing metabolite changes observed in human data on a different metabolite platform may result in inconsistent data. To conduct this project with another contractor would result in delays to the work already in process and duplication of costs already incurred. This is not a solicitation for competitive quotations. However, if any interested party, especially small businesses, believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on June 07, 2013. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (240)276-5401 or emailed to Afua Serwah- Asibey, Contract Specialist at afua.serwah-asibey@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP32510-59 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP32510-59/listing.html)
- Record
- SN03070834-W 20130525/130523235708-3d053994b42b30f6e252bccbd54907af (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |